Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.70 |
| ▸ | DRD2 | P14416 | 9/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | CCR3 | P51677 | 1/20 | 0.65 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477335 | 0.96 | DRD4 (0.66) | DRD4DRD2CYP2C9CYP2C19MAPT | |
| SCHEMBL5480942 | 0.88 | L3MBTL1 (0.61) | DRD4DRD2MAPTSMYD2 | |
| SCHEMBL5473741 | 0.88 | POLB (0.63) | DRD4DRD2CYP2C9CYP2C19MAPT | |
| SCHEMBL14430779 | 0.87 | LMNA (0.70) | DRD4DRD2CCR3SMYD2 | |
| SCHEMBL5487158 | 0.87 | SMYD2 (0.62) | DRD4DRD2MAPTSMYD2 | |
| SCHEMBL5481576 | 0.85 | NAMPT (0.61) | DRD4DRD2MAPTCCR3SMYD2 | |
| SCHEMBL3124560 | 0.85 | POLB (0.81) | MAPTSMYD2 | |
| SCHEMBL14005942 | 0.85 | DRD2 (0.64) | DRD4DRD2CCR3SMYD2 | |
| SCHEMBL5476704 | 0.84 | MCHR1 (0.58) | DRD4DRD2MAPTSMYD2 | |
| SCHEMBL5482155 | 0.84 | SMYD2 (0.68) | MAPTSMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | GRIN2C, TPH2, HTR5A | DRD4 12/4885DRD2 5/4885CYP2C9 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.